Summary by Moomoo AI
Aditxt, Inc., a biotech company, has responded to comments from the U.S. Securities and Exchange Commission (SEC) regarding its Preliminary Proxy Statement filed on May 29, 2024. The SEC's feedback, dated June 6, 2024, prompted Aditxt to file Amendment No. 1 to the Preliminary Proxy Statement. The amendment includes a quantification of the proposed increase to the number of authorized shares of common stock and the range of the proposed reverse stock split. Additionally, Aditxt has revised its disclosures in response to the SEC's request for more information on the issuance of shares related to its Series A-1 Convertible Preferred Stock and has removed Proposal No. 6 concerning the issuance of shares of Series C-1 Convertible Preferred Stock from the amendment. These changes were made to comply with SEC regulations and to clarify the company's proposals to its shareholders.
